Inovio Pharmaceuticals (INO)
(Delayed Data from NSDQ)
$6.48 USD
-0.21 (-3.14%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $6.47 -0.01 (-0.15%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth D Momentum F VGM
Price, Consensus and EPS Surprise
INO 6.48 -0.21(-3.14%)
Will INO be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for INO based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for INO
Editas Medicine (EDIT) Reports Q2 Loss, Misses Revenue Estimates
Castle Biosciences, Inc. (CSTL) Q2 Earnings and Revenues Beat Estimates
INO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Inovio (INO) Up as Lead Drug Gets Innovative Medicine Tag in UK
Inovio (INO) Soars 19.0%: Is Further Upside Left in the Stock?
Equillium, Inc. (EQ) Reports Q1 Loss, Tops Revenue Estimates
Other News for INO
INOVIO to Present at Upcoming Scientific Conference
Analysts Offer Insights on Healthcare Companies: Universal Health (UHS) and Inovio Pharmaceuticals (INO)
Inovio Pharmaceuticals (INO) Receives a Buy from Oppenheimer
Inovio price target lowered by $7 at Oppenheimer, here's why
Commit To Purchase Inovio Pharmaceuticals At $7, Earn 34% Annualized Using Options